SAMN03290946
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.500
- E2F_TARGETS+0.500
- G2M_CHECKPOINT+0.500
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.400
- INTERFERON_ALPHA_RESPONSE+0.400
- MITOTIC_SPINDLE+0.400
- TGF_BETA_SIGNALING+0.400
- INFLAMMATORY_RESPONSE+0.300
- INTERFERON_GAMMA_RESPONSE+0.300
- TNFA_SIGNALING_VIA_NFKB+0.300
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.300
- BILE_ACID_METABOLISM-0.200
- PANCREAS_BETA_CELLS-0.200
- WNT_BETA_CATENIN_SIGNALING-0.200
- CHOLESTEROL_HOMEOSTASIS-0.100
- ESTROGEN_RESPONSE_EARLY-0.100
- HEME_METABOLISM-0.100
- KRAS_SIGNALING_DN-0.100
- P53_PATHWAY-0.100
- ALLOGRAFT_REJECTION+0.000
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2208923 | — | — | 0.852 |
| 2 | SRR934962 | — | — | 0.842 |
| 3 | SRR934737 | — | — | 0.835 |
| 4 | SAMN03290942 | — | — | 0.834 |
| 5 | SRR934753 | — | — | 0.828 |
| 6 | MDT-AP-0309 | Med | Medulloblastoma | 0.827 |
| 7 | SRR934881 | — | — | 0.825 |
| 8 | SRR934886 | — | — | 0.824 |
| 9 | SRR934956 | — | — | 0.818 |
| 10 | TCGA-4Z-AA82-01A-11R-A39I-07 | — | — | 0.817 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.500 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.500 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.500 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.400 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.400 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.400 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.400 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.300 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.300 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.300 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.200 | Inavolisib | — uncovered |
| APOPTOSIS | 0.200 | Idelalisib | — uncovered |
| COAGULATION | 0.200 | Binimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.200 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.200 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.200 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.200 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.200 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.200 | Inavolisib | — uncovered |